elotuzumab

Known as: anti-CS1 monoclonal antibody HuLuc63, HuLuc63, Immunoglobulin G1, anti-(human SLAM family member 7 (CD2-like receptor activating cytotoxic cells, CD319 antigen)), humanized mouse monoclonal HuLuc63 gamma-1 heavy chain (222-214')-disulfide with humanized mouse monoclonal HuLuc63 kappa light chain (228-228'';231-231'')-bisdisulfide dimer 
A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2017
0204020052017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
In this proof-of-concept, open-label, phase 2 study, patients with relapsed/refractory multiple myeloma (RRMM) received… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
2015
2015
BACKGROUND Elotuzumab, an immunostimulatory monoclonal antibody targeting signalling lymphocytic activation molecule (SLAM… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2014
2014
Elotuzumab is a humanized monoclonal antibody specific for signaling lymphocytic activation molecule-F7 (SLAMF7, also known as… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Elotuzumab is a monoclonal antibody in development for multiple myeloma (MM) that targets CS1, a cell surface glycoprotein… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
This multicenter, first-in-human study evaluated the safety, tolerability, and pharmacokinetic and pharmacodynamic properties of… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE This phase I study evaluated elotuzumab, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE To evaluate the maximum-tolerated dose (MTD), safety, and efficacy of elotuzumab in combination with bortezomib in… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Currently, no approved monoclonal antibody (mAb) therapies exist for human multiple myeloma (MM). Here we characterized cell… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE We generated a humanized antibody, HuLuc63, which specifically targets CS1 (CCND3 subset 1, CRACC, and SLAMF7), a cell… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?